Publications by authors named "Nils Yngve Lycke"

Tuberculosis remains a major global health problem and efforts to develop a more effective vaccine have been unsuccessful so far. Targeting antigens (Ags) to dendritic cells (DCs) has emerged as a new promising vaccine strategy. In this approach, Ags are delivered directly to DCs antibodies that bind to endocytic cell-surface receptors.

View Article and Find Full Text PDF

Myasthenia gravis (MG) is an autoimmune neurological disorder typified by skeletal muscle fatigue and most often production of autoantibodies against the nicotinic acetylcholine receptor (AChR). The present study was undertaken to assess the extent of AChR-peptide recognition in MG patients using co-culturing (DC:TC) of autologous monocyte-derived dendritic cells (moDCs) and highly enriched CD4 T cells from the blood as compared to the traditional whole peripheral blood mononuclear cell (PBMC) cultures. We found that the DC:TC cultures were highly superior to the PBMC cultures for detection of reactivity toward HLA-DQ/DR-restricted AChR-peptides.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are trying to find better ways to help people with autoimmune diseases by restoring tissue-specific tolerance, but currently, no effective treatments are available for humans.
  • In an experiment with mice that have a condition called experimental autoimmune myasthenia gravis, a new treatment using a special protein seemed to significantly reduce the disease and improve symptoms.
  • This new protein, called mCTA1-T146, might be a good option for future treatments in people with myasthenia gravis because it showed promising results in boosting the immune system's ability to fight the disease.
View Article and Find Full Text PDF